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Abstract In addition to their role in glycosylation reactions,
UDP-sugars are released from cells and activate widely dis-
tributed cell surface P2Y14 receptors (P2Y14R). However, the
physiological/pathophysiological consequences of UDP-
sugar release are incompletely defined. Here, we report that
UDP-glucose levels are abnormally elevated in lung secre-
tions from patients with cystic fibrosis (CF) as well as in a
mouse model of CF-like disease, the βENaC transgenic (Tg)
mouse. Instillation of UDP-glucose into wild-type mouse tra-
cheas resulted in enhanced neutrophil lung recruitment, and
this effect was nearly abolished when UDP-glucose was co-
instilled with the P2Y14R antagonist PPTN [4-(piperidin-4-
yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl-2-naphthoic acid].
Importantly, administration of PPTN to βENaC-Tg mice re-
duced neutrophil lung inflammation. These results suggest
that UDP-glucose released into the airways acts as a local
mediator of neutrophil inflammation.
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Introduction
Nucleotides are released from cells in a regulated fashion,
activate cell surface purinergic receptors, and promote a broad
range of physiological processes [1, 2]. Purinergic receptors
comprise three subfamilies. The G protein-coupled A1R,
A2AR, A2BR, and A3R are activated by adenosine [3], the G
protein-coupled P2Y receptors are activated by ATP (P2Y2R,
P2Y11R), ADP (P2Y1R, P2Y12R, P2Y13R), UTP (P2Y2R,
P2Y4R), UDP (P2Y6R, P2Y14R), or UDP-sugars (P2Y14R)
[4], and the P2X receptors are ligand-gated ion channels acti-
vated by ATP [5].
Extracellular nucleotides and nucleosides regulate
mucociliary clearance (MCC) activities, thereby promoting
the primary innate defense mechanism that removes foreign
particles and pathogens from airway surfaces. Purinergic reg-
ulation in the airways is mediated mainly by the P2Y2R and
the A2BR [6]. Activation of the A2BR results in cyclic AMP-
dependent activation of the cystic fibrosis transmembrane reg-
ulator (CFTR) Cl− channel and stimulation of ciliary beat
frequency. Activation of the P2Y2R promotes inhibition of
Na+ absorption as well as CFTR-dependent and CFTR-
independent Cl− secretion, ciliary beating, and mucin secre-
tion [6, 7]. In addition, nucleotides within the airway surface
liquid (ASL) are potent pro-inflammatory signaling molecules
acting on purinergic receptors expressed on immune/
inflammatory cells or by promoting the release of cytokines
and other chemoattractants from lung epithelial cells [8–11].
Thus, the rates of nucleotide release and metabolism in
healthy airways are finely regulated to maintain effective
MCC without promoting airway inflammation.
Electronic supplementary material The online version of this article
(doi:10.1007/s11302-016-9524-5) contains supplementary material,
which is available to authorized users.
* Eduardo R. Lazarowski
eduardo_lazarowski@med.unc.edu
1 Marsico Lung Institute/Cystic Fibrosis Research Center, University
of North Carolina School of Medicine, 6007 Thurston-Bowles
Building, CB 7248, Chapel Hill, NC 27599-7248, USA
2 Department of Pharmacology, University of North Carolina School
of Medicine, Chapel Hill, NC, USA
3 Center for Environmental Medicine, Asthma, and Lung Biology,
University of North Carolina School of Medicine, Chapel Hill, NC,
USA
4 Laboratory of Bioorganic Chemistry, National Institute of Diabetes
and Digestive and Kidney Diseases, National Institutes of Health,
Bethesda, MD, USA
Purinergic Signalling (2016) 12:627–635
DOI 10.1007/s11302-016-9524-5
Mucus plugging, infection, and neutrophil inflammation in
the lung are pathological features of chronic inflammatory
lung diseases such as cystic fibrosis (CF) and chronic bron-
chitis [CB, a form of chronic obstructive lung disease
(COPD)]. While polymorphonuclear neutrophils (PMN) are
key players in fighting infections, they also are major contrib-
utors to the inflammatory response causing lung destruction in
CF and COPD [12]. Failure to effectively manage lung in-
flammation in CF and COPD is due, in part, to a limited
understanding of the processes responsible for neutrophil re-
cruitment, activation, and clearance in diseased airways.
The P2Y14R is a Gi-coupled receptor that is activated by
UDP-sugars with a relative potency order of UDP-glucose >
UDP-galactose > UDP-glucuronic acid > UDP-N-
acetylglucosamine [13, 14]. UDP also is an agonist of this
receptor, but ATP, UTP, or other naturally occurring nucleo-
side 5′- di- or triphosphates have no P2Y14R activity [13–16].
P2Y14R mRNA expression has been reported in the brain and
several peripheral tissues [13], including the lung, circulating
neutrophils, and other immune/inflammatory cells [17–21].
Studies from our lab have illustrated the occurrence of reg-
ulated release of UDP-sugars from several cell types, includ-
ing airway epithelial cells [22–28]. Notably, enhanced UDP-
sugar release was observed in mucin-secreting cells. For ex-
ample: (i) primary cultures of human bronchial epithelial
(HBE) cells induced to develop goblet cell metaplasia by in-
fection with respiratory syncytial virus or treatment with in-
terleukin 13 (IL-13) exhibited enhanced release of UDP-
glucose concomitantly with increased mucin secretion [22];
and (ii) goblet cell-like Calu-3 cells exhibited enhanced
Ca2+-regulated exocytosis of mucin granules, which was ac-
companied by increased release of UDP-glucose [27].
Bronchoalveolar lavage fluids (BALF) from patients with
CF and control diseases exhibit robust accumulation of
UDP-sugars [24]. In spite of the apparent association between
UDP-sugar levels in airway surface liquids and mucin hyper-
secretion and inflammation, the pathophysiological conse-
quences of UDP-glucose release into the airways are not well
understood.
Two lines of evidence suggest that UDP-sugars accumulat-
ing in the airway/alveolar space potentially trigger neutrophil
infiltration in the lung. Müller and co-workers reported ex-
pression of P2Y14R mRNA in primary cultures of human
alveolar epithelial type II cells, as well as in immortalized
human lung epithelial cell lines [11]. They also showed that
addition of UDP-glucose to these cells resulted in enhanced
secretion of interleukin 8 (IL-8), a potent neutrophil
chemoattractant [11]. In addition, we recently demonstrated
that UDP-glucose promotes P2Y14R-mediated chemotaxis of
freshly isolated human neutrophils. Enhanced PMNmigration
was observed in response to UDP-glucose gradients, and this
activity was abolished when the P2Y14R antagonist PPTN
[4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl-
2-naphthoic acid] was included in the cell suspension buffer
[29, 30].We also showed that UDP-glucose-promoted chemo-
taxis in neutrophil-like HL60 cells was absolutely dependent
on the expression of P2Y14R in these cells and was abolished
by PPTN [29, 30].
Whether UDP-glucose acts as a pro-inflammatory media-
tor in the lung is not known. To this end, we examined the
effect of UDP-glucose administration on neutrophil lung in-
filtration in wild-type mice and used the mucin-hypersecreting
βENaC transgenic mouse to further investigate the effect of
PPTN on the spontaneous neutrophil lung inflammation asso-
ciated with this mouse model.
Materials and methods
Materials UDP-glucose (Fluka catalog # 94335) was pur-
chased from Sigma-Aldrich (St. Louis, MO); high-
performance liquid chromatography (HPLC) analysis indicat-
ed that UDP-glucose was not contaminated with ATP, UTP, or
other nucleotide-signaling molecules [29]. PPTN was synthe-
sized as previously described [30] and used as a
dimethylsulfoxide (DMSO) stock solution (100 mM), which
was stored at −20 °C. PPTN was freshly diluted in endotoxin-
free PBS before its administration to mice and an equivalent
dilution of DMSO in PBS was used as vehicle in control
animals.
SubjectsHealthy (n = 10) and CF (n = 8) adults were recruited
to provide sputum specimens. Healthy subjects were non-
smokers without a history of asthma or allergy. CF subjects
were at their baseline state of health and had not been treated
for acute infection or exacerbation in the prior 4 weeks. Five
of 8 CF subjects used cycling inhaled antibiotics chronically,
but no samples were collected during an Bon^ treatment peri-
od. All but one CF subject were pancreatic insufficient, and all
had moderate to severe lung disease. See Table 1 for addition-
al demographic features. All subjects were studied at the
University of North Carolina at Chapel Hill (Chapel Hill,
Table 1 Study subject demographics
Control CF
Subjects (M/F) n 4/6 3/5
Age range (years) 20–28 25–38
FEV1% predicted 102.3 ± 12.3 43.1 ± 8.3*
Sputum PMNs (cells/mg plug) 335 ± 539 16,060 ± 14,610**
Data are presented as mean ± SD. Neutrophil values were available for
seven CF patients
M male, F female, FEV1 forced expiratory volume in 1 s
* p < 0.0005; ** p < 0.005, relative to control
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NC, USA), and studies were approved by the Institutional
Review Board.
Sputum collection and processing Spontaneous sputum
from CF patients and induced sputum from healthy control
subjects were collected and processed as previously described
[31, 32]. Briefly, mucus plug was selected and weighted.
Aliquots were treated with Sputolysin (DTT) and 1 mM
EDTA, filtered, and centrifuged, and the cell-free supernatant
was stored at −80, until further nucleotide analysis.
Measurements of nucleotides in lung secretions UDP-glu-
cose concentration was measured using the UDP-glucose
pyrophosphorylase-catalyzed conversion of UDP-glucose
and 32PPi to [32P]UTP and glucose-1P; the resulting 32P-la-
beled species were quantified by HPLC, as described [28];
samples where supplemented with 25 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH
7.4, 2 mMMgCl2, and 2 mM CaCl2 prior UDP-glucose mea-
surements. ATP levels were quantified by the off-line lucifer-
in-luciferase assay, using a GloMax luminometer (Promega,
Madison, WI) equipped with an automated injector. Sample
aliquots (20 μl) were transferred to a 96-well plate containing
150 μl H20/well and placed in the luminometer chamber.
Seventy-five microliters of the luciferin-luciferase buffer
[33] were subsequently injected, and luminescence was read
and integrated every 4 s using the GloMax® Discover soft-
ware. ATP calibration curves were performed in parallel to
samples.
Metabolism of UDP-glucose and ATP in sputum Sputum
samples (50 μl) were incubated at 37 °C with 5 μM ATP or
5 μM UDP-Glc in the presence of 25 mM HEPES, 2 mM
MgCl2 and 2 mMCaCl2. At the indicated times, samples were
heat inactivated and cooled on ice, and ATP and UDP-Glc
were quantified as indicated above.
Mice All mice used in these studies were on C57BL/6 back-
ground. For intratracheal instillation studies, wild-type mice
were purchased from Taconic (Hudson, NY). The airway spe-
cific βENaC transgenic (βENaC-Tg) mouse (overexpressing
the β-subunit of the epithelial sodium channel ENaC encoded
by the Scnn1b gene) [34] and littermate controls (wild type)
were obtained from the UNC CF Center Mouse Model Core.
Mice were housed in individually ventilated micro-isolator
cages, in a specific pathogen-free facility maintained at the
University of North Carolina at Chapel Hill, on a 12-h day/
night cycle. They were fed a regular chow diet and given
water ad libitum. Animal protocols were reviewed and ap-
proved by the Institutional Animal Care and Use Committee
of the University of North Carolina at Chapel Hill.
Intratracheal instillation Eight-week-old wild-type mice
were treated with sterile, endotoxin-free PBS (2 μl/g body
weight, 40–50 μl via intratracheal instillation) either alone or
containing 10 mM UDP-glucose, 10 μM PPTN, or both [35].
Animals were sacrificed 12 h after treatment (unless specified
otherwise) and bronchoalveolar lavage (BAL) obtained and
analyzed as described below.
Bronchoalveolar lavage and differential cell counts BAL
was performed as previously described [36]. Briefly, mice
were euthanized, the chest cavity opened, and PBSwas gently
injected (and retrieved) on the whole lung (800 μl in adult
mice; 200 μl in 13–14-day-old pups). This procedure was
conducted three times with an equal volume of PBS and frac-
tions were pooled. Cells were pelleted and the cell-free super-
natant (i.e., BALF) was stored at −80 °C for further analysis.
Cells were resuspended, counted with a hemocytometer, and
centrifuged (StatSpin CytoFuge 2) and the resulting cytospin
was stained for differential cell counting (Wright staining).
Cytospin images were obtained with a Nikon Microphot-SA
microscope interfaced with a DXM 1200 camera.
PPTN treatment of newborn βENaC-Tg mice Newborn
βENaC-Tg mice were subjected to intranasal instillation
[37] of PPTN (100 μMPPTN once a day, 1 μl/g body weight)
or equal volume of vehicle for 12 days. Pulmonary deposition
studies in newborn mice indicated that approximately 4 % of
drug doses delivered by intranasal instillation were deposited
into the lungs [37]. No differences in growth and survival
were observed between control and PPTN-treated mice.
Twelve hours after the last treatment, animals were sacrificed
and BAL performed as described above.
Cytokine measurements Mouse CXCL1/GRO alpha
(keratinocyte-derived cytokine, KC) was measured in BALF
by the UNC Immunotechnology Core (CGIBD Advanced
Analytics Core), using the developing reagent 3,3′,5,5′-
tetramethylbenzidine and the reader BioTek Synergy HT mi-
croplate spectrophotometer, BioTek’s Gen5.
Statistical analyses Statistical analyses were performed using
SigmaStat 3.1 or JMP 12.0.1. Comparisons between measure-
ments from two groups with significant difference in vari-
ances were performed using the Student t test assuming non-
equal variance, or non-parametric Wilcoxon rank-sum test.
Comparison between multiple groups was performed using
one-way analysis of variance (ANOVA) and differences
among the group means were assessed by the Tukey-Kramer
post-hoc test for multiple test correction. For inferential statis-
tics, p < 0.05 was considered statistically significant. Where
indicated, numeric values were log10-transformed with an
offset of +1 before inferential statistical analyses.
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Results
Increased levels of UDP-glucose in neutrophil-inflamed
CF lung secretions
Previous studies indicated robust levels of UDP-sugars in
in vivo airway surface liquid (BALF) from chronically dis-
eased lungs (e.g., cystic fibrosis) [24], but the extent to which
concentrations of UDP-sugars in CF airway secretions differ
from healthy controls is not known. Therefore, we examined
the nucleotide content in sputum samples (believed to reflect
secretions from the large airways) [38] obtained from CF pa-
tients with moderate or severe lung disease and from healthy
control subjects. As indicated in Table 1, CF patients exhibited
decreased pulmonary function (assessed as forced expiratory
volume, FEV1% predicted) and increased (but broadly
spread) number of neutrophils in sputum. UDP-glucose con-
centrations in control sputa were in the low nanomolar range
(UDP-glucose 9.5 ± 2.1 nM) but increased up to 11-fold in CF
(Fig. 1a), i.e., reaching concentration values capable of pro-
moting P2Y14R-mediated responses [29]. Although the small
sample size prevented us from establishing a correlation be-
tween UDP-glucose levels and lung function or sputum neu-
trophils within the CF group (Suppl. Fig. 1), the data suggest
an association between CF lung disease and ASL UDP-
glucose.
ATP levels seemed to increase in CF but were not signifi-
cantly different between CF and control samples (Fig. 1).
Ecto-nucleotidases expressed on (or secreted/shed from) epi-
thelial cells and inflammatory cells [29, 39, 40] could have
contributed to the pattern of nucleotide accumulation ob-
served in control and CF sputum. To gain an insight into
potential metabolism differences between ATP and UDP-
glucose in lung secretions, rates of ATP and UDP-glucose
hydrolysis were assessed in sputum supernatants. Incubation
of control sputum with ATP resulted in 23 ± 5, 68 ± 9, and
78 ± 10 % hydrolysis after 10, 20, and 60 min, respectively
(Fig. 1b). ATP hydrolysis increased considerably (to 61 ± 14,
89 ± 7, and 95 ± 4% at 10, 20, and 60min, respectively) in CF
sputum. ATP half-life value in CF sputum (t1/2 = 7.3 min) was
3-fold shorter than ATP t1/2 value in control samples
(23.2 min) (Fig. 1b). In contrast to ATP, UDP-glucose
remained essentially unchanged in both control and CF sputa
after 60 min (Fig. 1b).
CF/CB-like diseased mouse airways contain elevated
levels of UDP-glucose
Overexpression of the epithelial Na+ channel β-subunit
(Scnn1b gene, βENaC protein) in transgenic mouse airways
(βENaC-Tg mice) results in epithelial Na+ hyperabsorption,
airway dehydration, impaired mucus clearance, and airway
inflammation [34, 41]. This phenotype recapitulates many
features of CF and other chronic airway diseases [34, 41].
For example, βENaC-Tg mice exhibit signs of chronic bron-
chitis, with macrophage and neutrophil accumulation in the
lumen of the conducting airways and elevated neutrophil
counts in BAL [34, 41]. Our data indicate that the βENaC-
Tg mouse exhibits enhanced levels of UDP-glucose in BALF.
As shown in Fig. 2, UDP-glucose concentrations in BALF
from wild-type mice were 17 ± 14 nM, but levels increased
to 87 ± 15 nM in BALF from βENaC-Tg littermates. Taking
into account the substantial ASL dilution occurring during
BAL procedures, extracellular levels of UDP-glucose in
βENaC-Tg mouse lungs likely reach concentrations capable
of promoting robust activation of P2Y14R. ATP levels were
not statistically elevated in βENaC-Tg BALF (Fig. 2), likely
reflecting hydrolysis of released ATP.
Fig. 1 Elevated UDP-glucose levels in CF sputa. Nucleotide levels (a)
and nucleotide metabolism rates (b) were assessed in sputum samples
obtained from ten control (CTL) subjects and eight CF patients. The
data are expressed as mean ± SEM. An asterisk symbol indicates
p < 0.05; a double-barred pipe symbol indicates p < 0.005 against CTL.
UDP-Glc UDP-glucose
Fig. 2 βENaC-Tg mouse exhibits enhanced levels of UDP-glucose in
BALF. Levels of UDP-glucose (n = 8) and ATP (n = 4) were assessed in
BALF from 5-week-old wild-type and βENaC-Tg mice (mean ± SD;
*p < 0.05)
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UDP-glucose promotes neutrophil lung inflammation
The observation that UDP-glucose concentrations are elevated
in lung secretions from neutrophil-inflamed airways prompted
us to investigate a potential pro-inflammatory action of UDP-
glucose in the lung. UDP-glucose or PBS was administrated
to the lungs of wild-type mice via tracheal instillation and
BAL was performed after 12 h. BAL obtained from PBS-
treated mice exhibited little or no neutrophils, and alveolar-
resident macrophages were the predominant cells recovered in
these lavages (Fig. 3a, b) [36]. In contrast, instillation of UDP-
glucose resulted in a robust increase of neutrophils in BAL
after 12 h (Fig. 3a, b). Similar effects of UDP-glucose were
also observed after pre-treatment of UDP-glucose with apy-
rase to eliminate potential contamination with ATP/UTP [29]
(not shown). Time-course experiments indicated that maximal
PMN recruitment occurred within 12 h following UDP-
glucose instillation; neutrophil levels declined considerably
after 24 h (Fig. 3c).
We recently reported that the naphthoic acid derivative
PPTN is a high-affinity competitive antagonist of the
P2Y14R that does not interact with any of the other seven
P2Y receptor subtypes [30]. UDP-glucose-stimulated neutro-
phil lung infiltration was almost completely blocked when the
UDP-sugar was co-instilled with PPTN (Fig. 4). These results
strongly suggest that UDP-glucose-stimulated neutrophil re-
cruitment in mouse lungs involves activation of the P2Y14R.
The P2Y14R antagonist PPTN reduces neutrophil
inflammation in the βENaC-Tg mouse
Having shown that administration of UDP-glucose resulted in
P2Y14R-dependent neutrophil recruitment in wild-type mice,
we asked whether the P2Y14R contributes to the spontaneous
inflammatory phenotype associated with the βENaC-Tg
mouse. Previous studies indicated that βENaC-Tg mouse
lung inflammation is acquired over the perinatal period [34,
41, 42]. Therefore, we examined the effect of PPTN on neu-
trophil lung recruitment after daily intranasal instillation of the
P2Y14R antagonist to neonatal mice for 12 days. BALs from
βENaC-Tg mice treated with PBS displayed elevated neutro-
phils (and eosinophils) relative to wild-type mice (Fig. 5a and
[36]). Levels of the neutrophil chemoattractant cytokine mKC
also were elevated (Fig. 5b), consistent with the inflammatory
phenotype described in 10-day-old βENaC-Tg mice [41, 42].
Notably, PMN infiltration and mKC levels were markedly
Fig. 3 UDP-glucose promotes neutrophil recruitment in mouse lungs.
PBS or UDP-glucose was instilled into wild-type mouse trachea and
BAL was performed after 12 h (a, b) or at the times indicated (c). a
Representative photomicrograph of BAL cytospin preparations.
Neutrophils are indicated with arrow heads; Wright staining
(magnification = 40×). b Differential cell counting (mean ± SD, n = 4,
*p < 0.05 against PBS). Mac macrophages, PMN neutrophils, Eos
eosinophils, Lym lymphocytes. C Time-course of UDP-glucose-
promoted neutrophil recruitment in the lung; the data are the
mean ± difference to the mean from a representative experiment
performed with duplicate samples; similar results were obtained in two
separate experiments
Fig. 4 The P2Y14R antagonist PPTN reduces UDP-glucose-promoted
neutrophil lung migration. PBS or UDP-glucose was instilled into wild-
type mouse tracheas with or without PPTN, as indicated, and BAL was
performed after 12 h. The data represent the mean ± SD, n = 4. *p < 0.01;
**p < 0.001
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reduced in βENaC-Tg mice treated with PPTN (Fig. 5a, b).
PPTN had no effect on macrophage and eosinophil counts
(Fig. 5a).
Discussion
Neutrophil infiltration and mucus plugs are a hallmark of lung
diseases such as COPD and CF [12, 31, 43, 44], but the mech-
anism of neutrophil lung recruitment in mucus-obstructed
lungs is incompletely understood. In the present study, we
demonstrate that UDP-glucose levels are abnormally elevated
in lung secretions from CF patients and from a mouse model
of CF/chronic bronchitis, the βENaC-Tg transgenic mouse
(Figs. 1 and 2). We also show that administration of UDP-
glucose into mouse lung resulted in robust accumulation of
neutrophils in BAL (Fig. 3).
Availability of PPTN provides an important molecular
probe for interrogation of the functional role(s) played by
the P2Y14R in lung physiology and pathophysiology. PPTN
acts as a high-affinity competitive antagonist of the P2Y14R
and does so without interacting with any of the other seven
P2Y receptor subtypes [30]. Furthermore, PPTN blocks UDP-
glucose-promoted chemotaxis of human neutrophils without
affecting responses to bacterial peptides [30]. Here, we show
that PPTN not only blocked the effect of exogenous UDP-
glucose on neutrophil lung recruitment (Fig. 4) but also atten-
uated the spontaneous neutrophil inflammation that character-
izes the βENaC-Tg mouse (Fig. 5). Collectively, these results
strongly suggest that UDP-glucose released into CF-like dis-
eased airways acts as a pro-inflammatory mediator, via stim-
ulation of the P2Y14R.
P2Y14R mRNA is expressed in human [45] and murine
[46] lungs [17, 46] and inflammatory cells [17–21], but the
identity of the cell type(s) potentially sensing UDP-glucose in
airway surface liquids is not known. We observed no P2Y14R
mRNA amplification in well-differentiated primary cultures
of bronchial epithelial cells (data not shown). However, rele-
vant to this study, Müller and co-workers reported that
P2Y14R mRNA is expressed in cultured human alveolar epi-
thelial type II cells and also reported that addition of UDP-
glucose to these cells resulted in enhanced secretion of IL-8
[11]. Our data indicating that PPTN decreased mKC levels in
the βENaC-Tg mouse BAL (Fig. 5) could reflect a contribu-
tion of P2Y14R-promoted cytokine release from alveolar epi-
thelial cells, upstream of neutrophil recruitment [47]. In addi-
tion to the above-discussed scenario, published gene expres-
sion analyses indicated high levels of P2Y14R mRNA in mu-
rine alveolar macrophages [48]. Therefore, activation of
P2Y14R on lung resident macrophages also potentially results
in production of pro-inflammatory cytokines leading to neu-
trophil recruitment.
We recently illustrated that the P2Y14R is functionally
expressed in freshly isolated blood neutrophils, promoting
cytoskeleton rearrangement, Rho activation, and cell migra-
tion [29, 30]. Therefore, an additional mechanism likely con-
tributing to UDP-glucose-promoted neutrophil lung inflam-
mation is via activation of the neutrophil P2Y14R. For exam-
ple, UDP-glucose released into ASL could diffuse through the
paracellular pathway generating trans-epithelial and trans-
endothelial gradients that direct neutrophils from the vascula-
ture to the airways. Alternatively, cytokines released from
alveolar cells and/or macrophages could guide neutrophils
out the blood vessels, and UDP-glucose could direct them into
the airways. Furthermore, UDP-glucose-stimulated neutro-
phils may produce and release chemoattractants such as leu-
kotriene B4 and IL-8, potentiating the recruitment of addition-
al neutrophils at the inflammation site.
What is/are the cellular source(s) of extracellular UDP-
glucose in the CF lung? UDP-sugars are synthesized in the
cytosol and translocated into the lumen of the secretory path-
way where they serve as substrates of glycosylation reactions.
Thus, one mechanism potentially contributing to UDP-
glucose accumulation in ASL is its release from vesicles as
co-cargo with exported glycoconjugates. Indeed, we have
shown that, by controlling the entry of UDP-sugars into the
Golgi, SLC35 nucleotide-sugar transporters contribute to the
vesicular release of UDP-sugars from cultured airway epithe-
lial cells [24]. Furthermore, goblet cell-rich airway epithelial
cell models exhibit enhanced release of UDP-glucose con-
comitantly with mucins, heavily glycosylated proteins. Thus,
the mucin hypersecreting airway epithelia likely are an impor-
tant source of UDP-glucose accumulation in CF sputa and
βENaC-Tg mouse BALF. However, we cannot rule out that
activated and/or necrotic/apoptotic inflammatory cells also
contributed to the enhanced levels of UDP-glucose observed
in these samples.
It is worth noting that, in most cases where regulated nu-
cleotide release was assessed, rates of UDP-glucose release
Fig. 5 PPTN reduces neutrophil lung infiltration and BALF mKC levels
in βENaC-Tg mice. Newborn βENaC-Tg mice were treated with PPTN
(n = 17) or vehicle (n = 16) for 12 days, as indicated in the BMaterials and
methods^ section. BAL was performed 24 h after the last treatment and a
cells and b mKC were quantified. The data represent the mean ± SE;
*p < 0.05 relative to vehicle
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were markedly lower than ATP release rates, whereas steady-
state levels of UDP-glucose were often higher than ATP levels
[28]. Differences in rates of extracellular metabolism account
for this apparent discrepancy. For example, ecto-nucleoside
triphosphate diphosphohydrolases (E-NTPDases) sequential-
ly dephosphorylate ATP to ADP and AMP (ATP→ ADP→
AMP + 2 phosphates) and are abundantly expressed on the
surface of most cell types [49], including airway epithelial
cells [39, 50] and neutrophils [51]. Alkaline phosphatase,
which is expressed on airway epithelial cells [52], sequentially
dephosphorylates ATP, ADP, and AMP. UDP-sugars are not
metabolized by E-NTPDase or alkaline phosphatase activities
[49]. An additional group of ecto-nucleotidases includes
members of the ecto-nucleotide pyrophosphatase/
phosphodiesterase (E-NPP) family. E-NPPs break down
UDP-sugars (UDP-sugar → sugar-1P + pyrophosphate) as
well as ATP (ATP→ AMP + pyrophosphate) [49]. Our pre-
vious studies with primary cultures of HBE cells indicated that
inorganic [32P]-phosphate, but not [32P]-pyrophosphate, was
the product of [32γP]ATP hydrolysis on these cells [53], sug-
gesting that E-NPP activities are not present on human airway
epithelia. Consistent with this observation, we observed no
hydrolysis of UDP-[3H]glucose after a 2-h incubation of this
radiotracer on primary HBE cells, whereas [32γP]ATP was
completely hydrolyzed (Lazarowski, unpublished). Our data
with CF lung sputum (Fig. 1B) indicated that, unlike ATP,
UDP-glucose was not hydrolyzed after 1 h, suggesting that
secreted/shed E-NTPDases and/or phosphatases, but not E-
NPPs, are present in the soluble phase of CF lung secretions.
Previous studies indicated that UDP-N-acetylglucosamine
is present in BALF isolated from patients with CF and other
inflammatory diseases at concentrations similar to UDP-
glucose concentrations [24]. On a speculative basis, UDP-N-
acetylglucosamine and potentially UDP-galactose and UDP-
glucuronic acid may contribute to P2Y14R-dependent lung
phenotypes. However, given the low P2Y14R agonist potency
exhibited by these UDP-sugars, relative to UDP-glucose [13,
54], UDP-glucose predictably is the most important autocrine/
paracrine regulator of P2Y14R-mediated lung inflammation.
Recent studies examining P2Y14R-dependent second messen-
ger formation in model cell lines revealed that UDP is a very
potent agonist of this receptor [15]. However, since UDP
serves as a substrate of most E-NTPDases [49], it is unlikely
that the concentration of extracellular UDP approaches that of
UDP-sugars under most physiological and pathological con-
ditions. Collectively, our findings suggest that UDP-glucose is
a highly stable pro-inflammatory mediator present in CF-like
diseased airways.
In summary, this study indicates that UDP-glucose levels
are elevated in CF and CF-like lung secretions and that ad-
ministration of UDP-glucose into mouse lungs results in neu-
trophil inflammation. The hypothesis that nucleotide-sugars
act as pro-inflammatory signaling molecules in the lung is
further supported by the observation that a P2Y14R-selective
antagonist reduces the spontaneous neutrophil lung inflamma-
tion associated with the CF-like βENaC mouse. The extent to
which P2Y14R expressed on lung epithelial cells, alveolar
macrophages, and neutrophils contribute to this phenotype
remains to be elucidated.
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